The present disclosure provides fluorogenic compounds useful for preparing fluorescent calcium ion indicators, the fluorescent indicators themselves, and the use of the fluorescent indicators in methods of detection, discrimination and quantification of metal ions. The subject fluorogenic compounds and fluorescent ion indicators can include a chelating group based on a 2-aminophenoxyethylene glycol 2-aminoethyl ether, N,N,N′,N′-tetraacetic acid (PEGTA) moiety or precursor thereof where the phenyl group of the PEGTA is substituted with or fused with a fluorophore moiety of interest. The subject methods find use in the detection of intracellular calcium ions. Also provided are kits for use in practicing the subject methods.

The present disclosure provides fluorogenic compounds useful for preparing fluorescent calcium ion indicators, the fluorescent indicators themselves, and the use of the fluorescent indicators in methods of detection, discrimination and quantification of metal ions. The subject fluorogenic compounds and fluorescent ion indicators can include a chelating group based on a 2-aminophenoxyethylene glycol 2-aminoethyl ether, N,N,N′,N′-tetraacetic acid (PEGTA) moiety or precursor thereof where the phenyl group of the PEGTA is substituted with or fused with a fluorophore moiety of interest. The subject methods find use in the detection of intracellular calcium ions. Also provided are kits for use in practicing the subject methods.

The disclosure provides compounds of formula (I):

##STR00001##

said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

The disclosure provides compounds of formula (I):

##STR00001##

said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

The present application relates to a compound of a formula (I) which contains a spirobifluorene basic structure condensed onto a benzofuran unit. The application furthermore relates to a process for the preparation of the compound of the formula (I), and to the use of the compound of the formula (I) in an electronic device.

The present application relates to a compound of a formula (I) which contains a spirobifluorene basic structure condensed onto a benzofuran unit. The application furthermore relates to a process for the preparation of the compound of the formula (I), and to the use of the compound of the formula (I) in an electronic device.

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.